Atara Biotherapeutics Inc

NASDAQ:ATRA  
4.45
-0.29 (-6.12%)
4:49:10 PM EDT: $4.53 +0.08 (+1.80%)
Earnings Announcements

Atara Biotherapeutics Announces Third Quarter 2022 Financial Results, Operational Progress

Published: 11/08/2022 21:24 GMT
Atara Biotherapeutics Inc (ATRA) - Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress.
Atara Biotherapeutics Inc Q3 Loss per Share $0.82.
Atara Biotherapeutics - Phase 1 Study of Ata2271 Enrollment Resumed.
Atara Biotherapeutics - Believes Its Cash and Investments As of September 30, 2022, Will Be Sufficient to Fund Co Planned Operations Into Q1 2024.
Atara Biotherapeutics - Cash, Cash Equivalents & Short-term Investments As of Sept 30, 2022 Totaled $265.4 Million Versus $331.3 Million As of June 30, 2022.
Revenue is expected to be $26.4 Million
Adjusted EPS is expected to be -$0.58

Next Quarter Revenue Guidance is expected to be $5.19 Million
Next Quarter EPS Guidance is expected to be -$0.75

More details on our Analysts Page.